GlassScriptPhysician profile
Nelson J Mangione
NPI 1164504544
$570.92
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $46.57 · 2021: $107 · 2022: $26.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $156.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.90 | 2019-2021 | |
| Boston Scientific Corporation | $30.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.65 | 2019 | |
| Abbott Laboratories | $26.98 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.87 | 2019 | |
| Amgen INC. | $21.68 | 2019 | |
| Pfizer INC. | $19.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.80 | 2019 | |
| Lundbeck LLC | $17.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.05 | 2019 | |
| Daiichi Sankyo INC. | $16.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2019 | |
| Amarin Pharma, INC. | $13.81 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Mangione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.